English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

T he initial National Heart, Lung, and Blood Institute (NHLBI) Percutaneous Transluminal Coronary Angioplasty (PTCA) registry was established when the technique was in its infancy. The initial PTCA registry had the strong endorsement and support of the innovator of coronary angioplasty, Dr. Andreas Gruentzig.1 The registry tracked the early experience and development of this innovative technique from 1977 to 1981. The goals of the founders of the registry were to define appropriate patients for the procedure and evaluate early success, complication rates, and late followup. It was anticipated that the registry data would be used to design a controlled clinical trial to

circulation

The "second generation" NHLBI Percutaneous Transluminal Coronary Angioplasty Registry. Have we established the role for PTCA in treating coronary artery disease?